Patent · US Active

VEGF-binding fusion proteins and therapeutic uses thereof

US7972598B2 · kind B2 · utility

63Cited by

5References

1Claims

0Family size

Assignee

REGENERON PHARMACEUTICALS, INC. · US

Inventors

Thomas Daly · New City, US
James P. Fandl · Lagrangeville, US
Nicholas J. Papadopoulos · Lagrangeville, US

Key dates

Filing date	Nov 23, 2009
Grant date	Jul 5, 2011
Priority date	—
Expiry date	Nov 23, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Fusion proteins which bind and inhibit vascular endothelial growth factor (VEGF). The VEGF-binding fusion proteins are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.